Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Better Together: BioCryst, Idera Merge To Improve Rare Disease Position

Executive Summary

New company will have pair of Phase III candidates, an immuno-oncology licensing opportunity, strong experience in hereditary angioedema and roughly $243m in cash to position itself as a rare disease stronghold.

Advertisement

Related Content

BioCryst’s Oral Therapy For HAE Attacks On Track With Exploratory Phase II Success
Deal Watch: BioCryst Shareholder Dissent Scuttles Planned Merger With Idera
Pharma Q4 Results Preview: Shire, Bayer, Merck KGaA
Deal Watch: Sanofi Finds Ideal 'Partner' For Leukine
Products For Flu, Lung Cancer, HIV And TTP Enter Final Stages Of Assessment In EU
Shire Sees Another Way To Compete With CSL Behring In HAE With New Version Of Cinryze
BioCryst Flu Treatment’s Success May Hinge On Government Contract

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC100245

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel